M6P Therapeutics Presented Data on M041, A Recombinant Enzyme Therapy, for the Treatment of Sanfilippo B Syndrome at MPS 2021 | Proteins and Peptides

–
Leveraging the Company’s proprietary S1S3 bicistronic expression platform, M041 is co-expressed human NAGLU and S1S3, resulting in NAGLU
M6P –
–
With increased efficiency to phosphorylate lysosomal enzymes, M041 is a potential novel recombinant enzyme therapy for Sanfilippo B syndrome –
ST. LOUIS, MO, USA I July 28, 2021 IM6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced pre-clinical proof-of-concept data on M041 in a poster presentation by Patricia Dickson, M.D., Centennial Professor of Pediatrics and Chief, Division of Genetics and Genomic Medicine, Washington University of St. Louis, titled “

Related Keywords

,Patricia Dickson ,Pawel Krysiak ,Washington University Of St ,Division Of Genetics ,International Symposium ,Therapeutics Presented Data ,Recombinant Enzyme Therapy ,Sanfilippob Syndrome ,United Statesi July ,Centennial Professor ,Genomic Medicine ,Washington University ,Annual International Symposium ,Related Diseases ,பாட்ரிசியா டிக்சன் ,வாஷிங்டன் பல்கலைக்கழகம் ஆஃப் ஸ்டம்ப் ,பிரிவு ஆஃப் ஜெநெடிக்ஸ் ,சர்வதேச சிம்போசியம் ,நூற்றாண்டு ப்ரொஃபெஸர் ,வாஷிங்டன் பல்கலைக்கழகம் ,ஆண்டு சர்வதேச சிம்போசியம் ,தொடர்புடையது நோய்கள் ,